Trials / Unknown
UnknownNCT05620498
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
An Open Phase II Clinical Study of Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tislelizumab+lenvatinib+GMOX | tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 |
| DRUG | tislelizumab+GEMOX | tislelizumab+GEMOX |
Timeline
- Start date
- 2022-09-08
- Primary completion
- 2023-06-30
- Completion
- 2024-03-31
- First posted
- 2022-11-17
- Last updated
- 2022-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05620498. Inclusion in this directory is not an endorsement.